{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"13"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"16"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"13"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"9"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"13"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"12"},{"groupId":"OG011","value":"16"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs are presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG008","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG009","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG010","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG011","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated population included all participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4.5 years","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}